drugset / Trial / NCT04999878
A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
NaSingle-groupOpen-labelTreatment
Summary
To observe the efficacy and safety of Ruxolitinib and Etoposide combined with DDGP regimen ( cis-Platinum, Dexamethasone, Gemcitabine and Pegaspargase) in the first-line induction therapy of T cell lymphoma and NK/T cell lymphoma-associated hemophagocytic syndrome.
Timeline
- Start
- 2021-05-30
- Primary completion
- 2023-06-30
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 2.5 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg | Intravenous |
| Subject | Gemcitabine | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 unknown | — |
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |